Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Shortage Legislation Gains Momentum With Bipartisan House Bill

Executive Summary

Momentum is increasing for efforts to require manufacturers to give advance warning of a drug shortage with legislation now filed in both houses of Congress.

You may also be interested in...



Compounding Hearings Are First Step In Creating Active Legislative Ingredients

Congress will explore causes and potential policy solutions to the meningitis outbreak at the New England Compounding Center in back-to-back hearings, but any legislation increasing FDA regulatory authority faces a long road.

Drug Shortage Provisions In Draft PDUFA Bill Would Expedite Major Manufacturing Changes

FDA would have 60 days to review major changes and could “deem” them compliant with current good manufacturing practices so long as the facility has a plan and resources to achieve full compliance and institutes quality control measures under draft legislation being developed by the House Energy and Commerce Committee.

Drug Shortage Provisions In Draft PDUFA Bill Would Expedite Major Manufacturing Changes

FDA would have 60 days to review major changes and could “deem” them compliant with current good manufacturing practices so long as the facility has a plan and resources to achieve full compliance and institutes quality control measures under draft legislation being developed by the House Energy and Commerce Committee.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053528

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel